A Phase 2 interventional study of GAL-101 and Placebo in Geographic Atrophy of the Macula, sponsored by Galimedix Therapeutics Inc. Recruiting at 24 sites in 8 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Galimedix Therapeutics Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Geographic Atrophy with a site in Germany — 9 open to participants now, 12 under way, 3 of them phase 3. Geographic Atrophy · Germany.
Among the 40 studies in Geographic Atrophy with a site in Germany, this one is the 24th largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2025, is one of 13 in phase 2, reaches primary completion later than 4 of the 11 other live ones, and was the 35th registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →9 of the 40 studies in Geographic Atrophy with a site in Germany are open now. Recruiting first, the newest first:
Okuvision GmbH · Sites in Germany
Ages 60+
Novartis Pharmaceuticals · Sites in Germany, United States, Argentina and 16 more countries
Ages 50+
ADARx Pharmaceuticals, Inc. · Sites in Germany, United States, Australia and 9 more countries
Ages 60+
ONL Therapeutics · Sites in Germany, United States, Austria and 9 more countries
Ages 55+
Regeneron Pharmaceuticals · Sites in Germany, United States, Australia and 8 more countries
Ages 50–85
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 14 · Phase 3 13 · Phase 4 2
First in 2000; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 272 across the 33 interventional studies, 202 across the 7 observational. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 40 have an industry lead sponsor. The 10 most frequent:
Galimedix Therapeutics Inc is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Galimedix Therapeutics Inc has 1 study filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
2 of the studies in Geographic Atrophy with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT04796545VisionCare, Inc.Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies in Geographic Atrophy with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the growth of GA and prevent it from reaching the fovea. GAL-101 is given as eyedrops. eDREAM patients will administer study eyedrops every day. Patients will be assigned by chance (randomly) to receive either eye-drops that contain the new medication, GAL-101, or eyedrops without the active drug (Placebo). Neither patients nor doctors will know which treatment was assigned to each patient until the end of the study.
In this study, if both eyes qualify for the study, the eye with the better BCVA will be defined as the study eye. If both eyes qualify for the study and have identical BCVA, then the eye with higher baseline peripheral retinal degenerations (PRD) will be defined as the study eye. If baseline PRD is identical, then the right eye (OD) will be defined as the study eye. Only the study eye will be dosed with the Investigation Medicinal Product (IMP).
During visits, patients will administer 3 applications of 1 drop of GAL-101 or a matching Placebo that does not contain the active pharmaceutical ingredient (API) at 5-minute intervals (i.e., 1st application, wait 5 minutes, 2nd application, wait 5 minutes, 3rd application), under the supervision of trained and authorized study personnel. In between visits, patients will be instructed to administer 2 applications of 1 drop at 5-minute intervals once a day.
The study will be comprised of a 12- to 24-month treatment period determined individually according to patients' overall placement in global study randomization. All patients will participate at least 12 months of treatment. The visit schedule includes the following: Screening visits (Visit 1a and 1b) for image capture and confirmation of study eligibility by a reading center; Baseline/Randomization/Day 1 (Visit 2); a phone call at 2 weeks; and on-treatment clinic visits for safety and efficacy evaluations at 1 month, 3 months, 6 months, 9 months, and 12 months. Patients will continue to attend on-treatment clinic visits at 3-month intervals after 12 months until the last patient randomized in the study has completed 12 months of study treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with non-foveal GA secondary to non-neovascular AMD in the study eye, as confirmed by the reading center
Exclusion Criteria:
Use of rigid contact lenses within 1 month before Visit 1a or planned use during the study period
Non-study Eye:
BCVA of \<5 letters using ETDRS chart (i.e., 20/800 Snellen equivalent)
Either Eye:
Underwent treatment for AMD within 6 months before Visit 1a
General Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval
Drug: GAL-101
Patient will apply daily 2 eye drops ofPlacebo at 5 minutes interval
Drug: Placebo
Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval
Patient will apply daily 2 eye drops of Placebo at 5 minutes interval
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in GA lesion size.
Comparison between groups of annual rate of change in the area of GA as measured by fundus autofluorescence (FAF).
Time frame: From baseline to last on-treatment visit (48 up to 96 weeks)
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in photoreceptor degeneration (PRD) in eyes with GA
Comparison between groups of annual rate of change in the area of PRD as measured by optical coherence tomography (OCT)
Time frame: From baseline to last on-treatment visit (48 up to 96 weeks)
Not enrolling at this site — choose another above.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Mar 2028, 38 months after the start.
Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 54. This study's planned 38 months is close to that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Mar 2027 → Mar 2028 and completion May 2027 → May 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Galimedix Therapeutics Inc